II. Indications
-
Insomnia
- Short-term use only
III. Class
- Short Acting Benzodiazepine
IV. Dose
- Adult: 0.125 to 0.25 mg orally at bedtime for 7 to 10 days as needed
- Elderly: 0.125 mg orally at bedtime for 7 to 10 days as needed
- Maximum: 0.5 mg at bedtime (0.25 mg is sufficient in most patients)
VI. Precautions
- Reports of Psychosis and Violence
- Associated with high dose Halcion (>1 mg)
- Likely to be as safe as other Benzodiazepines
VII. Safety
- Pregnancy Category X
- Avoid in Lactation
- Schedule IV Controlled Substance
VIII. Resources
IX. References
- (2019) Med Lett Drugs Ther 61(1578): 121-6
- (2020) Presc Lett, Resource #361206, Appropriate Use of Benzodiazepines
- Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 55
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
Images: Related links to external sites (from Bing)
Related Studies
triazolam (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
TRIAZOLAM 0.125 MG TABLET | Generic | $1.16 each |
TRIAZOLAM 0.25 MG TABLET | Generic | $1.01 each |
Ontology: Triazolam (C0040879)
Definition (NCI) | A triazolobenzodiazepinederivative with sedative-hypnotic property. Triazolam interacts directly with a specific site on the gamma-aminobutyric acid (GABA)-A-chloride-ionophore receptor complex located on the neuronal membrane. Binding causes allosteric modification of the receptor and modulation of its affinity for the inhibitory neurotransmitter GABA. This results in enhancement of synaptic actions of GABA and includes an increase in the frequency of chloride channel openings, increased chloride ion conductance, membrane hyperpolarization and ultimately synaptic inhibition and decreased neuronal excitability. |
Definition (CSP) | 8-chloro-6-(2-chlorophenyl)-1-methyl- 1,2,4-triazolobenzodiazepine. |
Definition (MSH) | A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D014229 |
SnomedCT | 111128007, 386984001 |
LNC | LP16298-9, MTHU003366 |
English | Triazolam, 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-(2-chlorophenyl)-1-methyl-, triazolam, clorazolam, triazolam (medication), sedatives triazolam, TRIAZOLAM, Triazolam [Chemical/Ingredient], 8-Chloro-6-(2-chlorophenyl)-1-methyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine, Clorazolam, Triazolam (product), Triazolam (substance) |
Swedish | Triazolam |
Czech | triazolam |
Finnish | Triatsolaami |
Russian | TRIAZOLAM, ТРИАЗОЛАМ |
Japanese | トリアゾラム |
Polish | Triazolam |
Spanish | triazolam (producto), triazolam (sustancia), triazolam, Triazolam |
French | Triazolam |
German | Triazolam |
Italian | Triazolam |
Portuguese | Triazolam |
Ontology: Halcion (C0733624)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D014229 |
English | Pfizer Brand of Triazolam, Triazolam Pfizer Brand, halcion, Halcion |